Last 188.00
Change Today +3.00 / 1.62%
Volume 77.5K
LHG On Other Exchanges
Symbol
Exchange
Johannesburg
As of 11:00 AM 07/25/14 All times are local (Market data is delayed by at least 15 minutes).

litha healthcare group ltd (LHG) Snapshot

Open
$186.00
Previous Close
$185.00
Day High
$188.00
Day Low
$185.00
52 Week High
09/11/13 - $310.00
52 Week Low
05/16/14 - $155.00
Market Cap
1.1B
Average Volume 10 Days
123.5K
EPS TTM
$0.03
Shares Outstanding
559.6M
EX-Date
--
P/E TM
69.6x
Dividend
--
Dividend Yield
--
Current Stock Chart for LITHA HEALTHCARE GROUP LTD (LHG)

Related News

No related news articles were found.

litha healthcare group ltd (LHG) Related Businessweek News

No Related Businessweek News Found

litha healthcare group ltd (LHG) Details

Litha Healthcare Group Limited, a diversified healthcare company, offers a range of medical and pharmaceutical products to the public and private healthcare markets in Southern Africa. Its Litha Pharma division markets, sells, and distributes a range of healthcare products, including pharmaceuticals of original research and generics, OTC, and complementary medicines. The company’s Litha Medical division supplies medical consumables, capital equipment, and medical devices in the therapeutic areas of critical care, infection control, gynecology, obstetrics, pediatrics, ophthalmology, orthopedics and sports medicine, urology, surgery, forensics, infusion therapy, and wound care. Its Litha Biotech division imports and distributes pediatric and adult vaccines. The company was founded in 1992 and is headquartered in Midrand, South Africa. As of September 3, 2013, Litha Healthcare Group Limited operates as a subsidiary of Paladin Labs Inc.

279 Employees
Last Reported Date: 06/28/14
Founded in 1992

litha healthcare group ltd (LHG) Top Compensated Officers

Chief Executive Officer, Executive Director a...
Total Annual Compensation: R2.2M
Chief Financial Officer, Financial Director a...
Total Annual Compensation: R1.6M
Divisional Chief Executive Officer of Litha P...
Total Annual Compensation: R2.8M
Deputy Chief Executive Officer, Executive Dir...
Total Annual Compensation: R1.5M
Group Finance Executive and Company Secretary
Total Annual Compensation: R1.2M
Compensation as of Fiscal Year 2013.

litha healthcare group ltd (LHG) Key Developments

Litha Healthcare Group Limited to Consider MOI Amendments

Litha Healthcare Group Limited will consider the MOI Amendments of the company at the general meeting of shareholders to be held on June 10, 2014.

Litha Healthcare Group Limited Announces Consolidated Earnings Results for the Fourth Quarter and Year Ended December 31, 2013

Litha Healthcare Group Limited announced consolidated earnings results for the fourth quarter and year ended December 31, 2013. For the quarter, the company's revenue was ZAR 247.3 million compared with ZAR 237.5 million a year ago. Revenue increased in the quarter compared to fourth quarter 2012, mainly due to the strong performance of the Litha Medical division. Operating loss was ZAR 2.32 million compared with ZAR 10.3 million a year ago. Loss before taxation was ZAR 8.3 million compared with ZAR 19.7 million a year ago. Loss from continuing operations was ZAR 8.4 million compared with ZAR 15.1 million a year ago. Loss for the period was ZAR 8.95 million compared with ZAR 16.7 million a year ago. Loss attributable to equity holders of the company from continuing operations was ZAR 8.2 million or 1.4 ZAR cents per diluted share compared with ZAR 15.1 million or 2.7 ZAR cents per diluted share a year ago. Loss attributable to equity holders of the company was ZAR 8.7 million or 1.5 ZAR cents per diluted share compared with ZAR 16.8 million or 3.0 ZAR cents per diluted share a year ago. Headline loss from continuing operations was ZAR 8.15 million or 1.5 ZAR cents per share compared with ZAR 14.6 million or 2.6 ZAR cents per share a year ago. Headline loss was ZAR 8.7 million or 1.6 ZAR cents per share compared with ZAR 16.3 million or 2.9 ZAR cents per share a year ago. Cash flows from operating activities were ZAR 21.7 million compared with ZAR 2.5 million a year ago. EBITDA was ZAR 19.1 million compared with ZAR 21.8 million a year ago. This was mainly due to foreign exchange impacts throughout the Group and the commoditization of certain key generic products within the Litha Pharma division. For the year, the company's revenue was ZAR 1,045.3 million compared with ZAR 1,434.5 million a year ago. Operating profit was ZAR 46.9 million compared with ZAR 232.8 million a year ago. The decrease was mainly due to a once-off profit on deconsolidation of Biovac of ZAR 172 million, foreign exchange pressures and the commoditization of certain key generic products. Profit before taxation was ZAR 24.2 million compared with ZAR 215.8 million a year ago. Profit from continuing operations was ZAR 13.2 million compared with ZAR 204.4 million a year ago. Profit for the period was ZAR 13.5 million compared with ZAR 196.8 million a year ago. Profit attributable to equity holders of the company from continuing operations was ZAR 14.1 million or 2.4 ZAR cents per diluted share compared with ZAR 173.1 million or 36.2 ZAR cents per diluted share a year ago. Profit attributable to equity holders of the company was ZAR 14.4 million or 2.5 ZAR cents per diluted share compared with ZAR 165.5 million or 34.6 ZAR cents per diluted share a year ago. Headline earnings from continuing operations was ZAR 14.1 million or 2.4 ZAR cents per share compared with ZAR 30.96 million or 6.5 ZAR cents per share a year ago. Headline earnings were ZAR 14.4 million or 2.5 ZAR cents per share compared with ZAR 23.3 million or 4.9 ZAR cents per share a year ago. Cash flows from operating activities was ZAR 64.1 million compared with ZAR 153.9 million a year ago. EBITDA was ZAR 110.5 million compared with ZAR 127.9 million a year ago.

Litha Healthcare Group Limited Provides Earnings Guidance for the Year Ended December 31, 2013

Litha Healthcare Group Limited provided earnings guidance for the year ended December 31, 2013. The company reported that earnings per share is expected to be between 80% and 100% lower and headline earnings per share is expected to be between 40% and 60% lower than for the financial year ended December 31, 2012. This decrease in earnings is primarily attributable to the once-off profit of ZAR 171,529,531 recognized in 2012 associated with the deconsolidation of the Biologicals and Vaccines Institute of Southern Africa Pty Ltd. This once-off profit was included in earnings per share for the financial year ended December 31, 2012 and represented 79% of the 2012 earnings before taxation and the continued devaluation of the South African Rand which increased the cost of imported products.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
LHG:SJ 188.00 +3.00

LHG Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for LHG.
View Industry Companies
 

Industry Analysis

LHG

Industry Average

Valuation LHG Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact LITHA HEALTHCARE GROUP LTD, please visit www.lithahealthcare.co.za. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.